Vanguard Group Inc. Grows Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Vanguard Group Inc. lifted its holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 49.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,822,151 shares of the company's stock after purchasing an additional 1,261,920 shares during the period. Vanguard Group Inc. owned about 4.32% of Caribou Biosciences worth $18,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of CRBU. NewEdge Advisors LLC grew its position in shares of Caribou Biosciences by 187.3% in the first quarter. NewEdge Advisors LLC now owns 5,100 shares of the company's stock valued at $27,000 after purchasing an additional 3,325 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Caribou Biosciences by 88.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,871 shares of the company's stock worth $29,000 after buying an additional 3,218 shares during the last quarter. Royal Bank of Canada increased its stake in Caribou Biosciences by 52.3% during the 2nd quarter. Royal Bank of Canada now owns 8,106 shares of the company's stock worth $34,000 after buying an additional 2,785 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Caribou Biosciences by 168.4% during the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company's stock valued at $36,000 after acquiring an additional 2,475 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Caribou Biosciences in the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their price objective on Caribou Biosciences from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, March 19th.

Caribou Biosciences Price Performance

CRBU stock traded down $0.13 during midday trading on Monday, hitting $4.07. 1,609,048 shares of the company's stock were exchanged, compared to its average volume of 1,647,812. Caribou Biosciences, Inc. has a 1-year low of $3.44 and a 1-year high of $8.59. The business has a 50-day simple moving average of $6.10 and a two-hundred day simple moving average of $5.47.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.17). The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. As a group, research analysts anticipate that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.